FDA advisory committee

Pharma

FDA flags concerns about Ardelyx's kidney disease prospect

Ardelyx's problem, according to the FDA, is that tenapanor’s “magnitude of treatment effect appears less than that observed with approved drugs.”
Fraiser Kansteiner Nov 15, 2022 10:48am

GSK's Zejula FDA oncology AdComm canceled

Nov 9, 2022 11:23am

GSK's daprodustat gets FDA adcomm yes, no votes in CKD

Oct 26, 2022 7:07pm

FDA outlines risks of GSK's daprodustat for panel to discuss

Oct 25, 2022 11:48am

Amylyx's ALS drug finally approved by FDA

Sep 29, 2022 5:00pm

FDA adcomm votes down Secura's PI3K drug in CLL

Sep 23, 2022 3:06pm